Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.71 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1987660 | 0.83 | TAS1R3 (0.64) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL534385 | 0.83 | P2RX7 (1.00) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL457993 | 0.83 | NPC1 (0.84) | P2RX7NPC1RAB9APOLBMEN1 | |
| SCHEMBL28583422 | 0.82 | P2RX7 (0.97) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL738909 | 0.81 | P2RX7 (0.71) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL29615916 | 0.81 | P2RX7 (0.71) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL19155146 | 0.81 | NPC1 (0.60) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL738587 | 0.81 | P2RX7 (0.71) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL24857978 | 0.80 | P2RX7 (0.66) | P2RX7TAS1R3TAS1R1TAS1R2NPC1 | |
| SCHEMBL700898 | 0.80 | TAS1R3 (1.00) | TAS1R3TAS1R1TAS1R2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | P2RX7 3349/4885TAS1R3 3639/4885TAS1R1 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.